Nicholas J. Donoghoe - 14 Aug 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: EVP, CHIEF BUS/STRAT OFFICER
Issuer ticker: ABBV
Reported as of: 14 Aug 2026
Net transaction value: -$8,177,500
SEC form: 4
Accepted by SEC: 18 Aug 2026, 17:00:16 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe

Key filing fact

Nicholas J. Donoghoe filed Form 4 for AbbVie Inc. (ABBV) on 18 Aug 2026.

Key facts

This page summarizes Nicholas J. Donoghoe's Form 4 filing for AbbVie Inc. (ABBV).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Aug 2026, 17:00.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$8,177,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001762951 Primary reporting owner

Donoghoe Nicholas

Relationship: EVP, CHIEF BUS/STRAT OFFICER
Address: 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABBV transaction

Common Stock, $0.01 par value

Options Exercise

Transaction value
Shares: +32,710
Change %: +44%
Price: $79.02^*
Shares after: 107,140
Date: 14 Aug 2026
Ownership: Direct

ABBV transaction

Common Stock, $0.01 par value

Sale

Transaction value: $8,177,500
Shares: -32,710
Change %: -31%
Price: $250.00
Shares after: 74,430
Date: 14 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABBV transaction Derivative

Option (Right to buy)

Options Exercise

Transaction value
Shares: -32,710
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,710
Exercise price: $79.02
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022.